CSL

CSL Limited (CSL)

Market Closed
ASX ASX
- Market Cap
- P/E Ratio
2.7% Div Yield
645,818 Volume
- Eps
Want to track CSL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 56 days

Summary

CSL closed Friday higher, an increase of 2.88% from Thursday's close, completing a monthly decrease of -1.23%. Over the past 12 months, CSL stock lost -34.43%.
CSL pays dividends to its shareholders, with the most recent payment made on Oct 03, 2025. The next estimated payment will be in In 3 months on Apr 03, 2026 for a total of A$2.48466.
The last earnings report, released on Oct 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 08, 2026.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on ASX (AUD).

CSL Limited (CSL) FAQ

On which exchange is it traded?

CSL Limited is listed on ASX.

What is its stock symbol?

The ticker symbol is CSL.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 2.7%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Feb 08, 2026.

Has CSL Limited ever had a stock split?

No, there has never been a stock split.

CSL Limited Profile

Biotechnology Industry
Healthcare Sector
Dr. Paul F. McKenzie Ph.D. CEO
ASX Exchange
AU000000CSL8 ISIN
AU Country
32,698 Employees
9 Sep 2025 Last Dividend
- Last Split
- IPO Date

Overview

CSL Limited is a globally prominent biopharmaceutical and vaccine company with its roots firmly planted in Melbourne, Australia since 1916. The company has carved out a significant presence not only in its home country but also across vital markets in the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and beyond. CSL Limited operates with a strategic focus on research, development, manufacturing, marketing, and distribution of innovative biopharmaceutical and vaccine solutions. It is organized into three main segments: CSL Behring, CSL Seqirus, and CSL Vifor, each targeting specific healthcare needs worldwide. Additionally, CSL Limited actively engages in licensing its intellectual property, underscoring its contributions to advancing global healthcare technologies and treatments.

Products and Services

  • CSL Behring

    This segment caters to a variety of healthcare needs through its diverse portfolio of products. CSL Behring is renowned for its plasma products, contributing to therapies for immunodeficiencies and rare diseases. It also pioneers in gene therapies, offering cutting-edge treatments for genetic disorders. Furthermore, CSL Behring provides recombinant products, marking significant advances in biotechnology for therapeutic uses.

  • CSL Seqirus

    Specializing in influenza-related products, CSL Seqirus stands out for its proactive approach towards flu prevention and pandemic preparedness. It offers a breadth of seasonal flu vaccines, ensuring public health safety across the globe. Additionally, CSL Seqirus collaborates with governments worldwide, offering pandemic services and solutions aimed at combating influenza outbreaks efficiently and effectively.

  • CSL Vifor

    With a keen focus on iron deficiency and nephrology, the CSL Vifor segment advances medical treatments in these crucial therapeutic areas. By developing and distributing specialized products, CSL Vifor addresses a range of conditions related to kidney health and iron metabolism, providing essential solutions for patients suffering from these ailments.

Contact Information

Address: 45 Poplar Road
Phone: 61 3 9389 1911